Clifton C. Mo, MD, provides insight on the management of multiple myeloma and evaluates the role of current treatment regimens.
Case Based Peer Perspectives
Kami Maddocks, MD, reviews the case of a 74-year-old man with relapsed/refractory follicular lymphoma and discusses current treatment options.
Rafael Fonseca, MD, discusses the case of a 77-year-old woman with multiple myeloma, treatment approach for patients with newly diagnosed multiple myeloma, and the trials providing insight into the treatment of this disease.
Matthew Lunning, DO, presents a case study of a 71-year-old woman with relapsed/refractory diffuse large B-cell lymphoma.
Karen Reckamp, MD, comments on the management and treatment of a 68-year-old woman with ALK+ NSCLC, as well as data demonstrated in the ALTA-1L trial, use of brigatinib, and her own clinical experiences.
Joshua M. Bauml, MD, provides insight on the treatment of ALK fusion+ non-small cell lung cancer with tyrosine kinase inhibitors.
Erin Crane, MD, reviews the case of a 63-year-old woman with recurrent ovarian cancer and discusses treatment options, the Phase 3 NOVA trial, and the future of ovarian cancer treatment.
Natalie Callander, MD, presents a case of a 68-year-old man with multiple myeloma.
Adriana Rossi, MD, describes the treatment approach in caring for a 75-year-old woman with triple-class refractory multiple myeloma [RRMM] while highlighting results from the relevant DREAMM and SOHO studies.
A key opinion leader in hematology, Jonathan Kaufman, MD, provides insight into the case of a 75-year-old man with multiple myeloma and discusses treatment considerations, standard of care therapies, and recent clinical trial updates for the management of multiple myeloma.
Sagar Lonial, MD, FACP, presents a case of a 72-year-old man with heavily pretreated relapsed/refractory multiple myeloma and discusses treatment options for patients with this diagnosis who have failed multiple prior lines of therapy.
Shannon Westin, MD, analyzes the diagnosis and treatment of a 68-year-old woman with recurrent ovarian cancer.
Recommendations for using ruxolitinib to treat a 53-year-old patient with acute graft-versus-host disease whose disease progresses following previous treatment with steroid therapy.
Hematology/oncology expert, John P. Leonard, MD, describes the rationale for treating an elderly patient with relapsed/refractory follicular lymphoma with a PI3K inhibitor in the third-line setting.
Yi-Bin Chen, MD, reviews the case of a 50-year-old woman with steroid-refractory acute graft versus host disease (aGvHD) following allogeneic transplant and provides a discussion on treatment considerations for patients with aGvHD.
Nicholas Vogelzang, MD, FASCO, FACP, comments on managing an elderly patient with hormone-sensitive prostate cancer with apalutamide and ADT based on data demonstrated by the phase 3 TITAN trial.
Kartik Konduri, MD, reviews the case of a 68-year-old woman with small-cell lung cancer.
Sagar Lonial, MD, FACP, presents a case of a 78-year-old man with multiple myeloma and discusses the many facets of treatment for multiple myeloma in the elderly population.
Brian Hill, MD, reviews the case of a 73-year-old man with mantle cell lymphoma and discusses the latest data and treatment approaches.
Daniel Catenacci, MD, reviews the case of a 71-year-old man with gastric cancer.
Saad Usmani, MD, presents a case of a 75-year-old woman with multiple myeloma.
Saad Usmani, MD, presents a case of a 75-year-old woman with multiple myeloma.
Ticiana Leal, MD, presents a case of a 61-year-old man with small cell lung cancer.
Recommendations for using AR-targeted therapy as an approach when managing patients with metastatic castrate-sensitive prostate cancer.
Bassel El-Rayes, MD, reviews the case of a 66-year old man with gastric carcinoma and discusses the disease from diagnosis to unmet needs.
Andrew G. Gianoukakis, MD, of Harbor-UCLA Medical Center, describes the rationale for treating a patient with RAI-refractory differentiated thyroid cancer with systemic therapy.
John M. Burke, MD, of Rocky Mountain Cancer Centers, explains the rationale behind treating an elderly woman with relapsed diffuse large B-cell lymphoma with tafasitamab and lenalidomide after R-CHOP chemotherapy.
Gilles Salles, MD, reviews the case of a 74-year-old man with diffuse large B-cell lymphoma.
Robert Alter, MD, of John Theurer Cancer Center, describes the rationale for treating a 58-year-old male with advanced renal cell carcinoma with the combination of lenvatinib and everolimus following progression on first-line therapy.
A key opinion leader reviews the case of a 71-year-old woman with NTRK gene fusion thyroid cancer and considers novel therapies available for the management of her disease.